The fight against time: can we slow down ageing? - with Carina Kern

The lecture provides a valuable and accessible introduction to the complexity of ageing, effectively communicating the multifactorial nature of age-related diseases and the limitations of current medical approaches. Kern’s presentation is engaging and well-structured, using clear examples and analogies to explain scientific concepts. The Blueprint Theory of Ageing, while not yet widely established, is presented as a novel framework, and Kern appropriately acknowledges the need for further research. The discussion of AI in drug discovery is balanced, highlighting both its potential and the current data limitations. The talk references specific studies, such as the twin study and the ‘Cosmic Kidneys’ research, lending credibility to the content. However, some claims could benefit from more explicit citations during the talk, and the distinction between necrosis and other forms of cell death could be clarified. The ethical implications of longevity research are briefly touched upon but not deeply explored. Overall, the lecture is scientifically sound and thought-provoking, though it may oversimplify some aspects for a general audience. The inclusion of a Q&A session for supporters suggests a desire for deeper engagement, but the main talk stands alone as a solid overview.

The title accurately reflects the content, which focuses on the biology of ageing and potential interventions.

8/10

The talk is based on published research and the speaker's own work, with references to studies and a preprint. The content is presented clearly, but some claims lack detailed citations during the talk.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 02:00Introduction to ageing questions: is ageing universal, does it vary across species, and can it be altered?
• 05:00Examples of lifespan variation: mice, squirrels, primates, humans, bowhead whales, and hydra.
• 08:00Twin studies showing environmental factors affect ageing trajectory.
• 10:00Astronauts and accelerated ageing: effects of space on the body.
• 15:00Definition of ageing: tangible changes and two types of pathologies.
• 20:00Age-related diseases are multifactorial and often co-occur (multimorbidity).
• 25:00Economic impact of age-related diseases, e.g., kidney disease costs.
• 30:00Why no drugs are approved for ageing: lack of mechanistic insights and long trials.
• 35:00Limitations of standard drug discovery for ageing; need for new approaches.
• 40:00Introduction of the Blueprint Theory of Ageing and the role of necrosis.
• 45:00Potential of AI in drug discovery, with examples like AlphaFold and data challenges.
• 50:00Conclusion: Medicine 2.0 and the future of ageing research.

• Nature paper on necrosis — Referenced as a publication on necrosis and its role in ageing.
• Preprint on Blueprint Theory — Preprint introducing the Blueprint Theory of Ageing.
• LinkGevity LinkedIn — Company page for LinkGevity, founded by Carina Kern.
• RI Science Podcast — Podcast for further discussion.
• Q&A video — Exclusive Q&A for Science Supporters.

• Hallmarks of Aging — Supports the multifactorial nature of ageing.
• Senolytics — Related to anti-ageing interventions.

• NIH stance on ageing as disease — Some comments suggest NIH does not classify ageing as a disease, which contrasts with the talk's implication that ageing should be treated.

• www.rigb.org
• www.rigb.org